The 12 month study of 430 overweight men and women (BMI of 30-43 kg/m2), was designed to assess the effectiveness of Xenical in patients who are responsive to treatment. Patients who achieved 5 per cent (approximately 5kg) weight loss after 3 months and maintained this after a further 3 months of Xenical treatment, were followed for one year. During this time weight loss and other health improvements, such as reductions in blood pressure, were assessed. The results suggest that the efficacy of Xenical in a real-life clinical practice setting is even greater than that demonstrated previously in clinical trials:

• The greatest weight loss was seen in the first four weeks of treatment, with an average weight loss of 4.1 kg
• Three out of four people achieved 5 per cent weight loss by month three, losing an average of 8kg
• By month 6, 92 per cent of these people had maintained at least 5 per cent weight loss, with an average weight loss of 10.9kg.
• The average weight loss after one year was 11.6 kg. One in two patients in the study lost more than 10 per cent of their initial weight, and over 8 in ten people lost more than 5 per cent an amount of weight loss shown to clinically improve the health and well-being of overweight people 2

Commenting on the results, lead study investigator Professor Hermann Toplak from the Karl-Franzens-Universitt, Graz, Austria said These results demonstrate the significant benefits of rapid and continuous weight loss with Xenical in a clinical practice setting. Patients who respond rapidly to treatment continue with treatment and achieve long-term success.

Results also demonstrated significant health gains associated with weight loss with Xenical. Specifically, people treated with
'"/>

Contact: Patrick Ward
patrick.ward@shirehealthinternational.com
44-207-471-1527
Shire Health International
28-May-2002